Objective To explore the expression and clinical significance of serum golgi protein 73 (GP73) in patients with primary hepatic carcinoma (PHC). Methods 47 patients with PHC (group PHC) and 40 patients with liver cirrhosis (group liver cirrhosis) were recruited in this study. Serum GP73 of the two groups were detected using enzyme-linked immunosorbent assay (ELISA) and Alpha-Fetal protein (AFP) of the two groups were detected using the electrochemiluminescence method. The results were compared. Results The serum levels of GP73 (220.44±89.71) μg/L or AFP (404.06±135.43) μg/L was significantly increased in hepatic carcinoma group compared with GFP73 (112.67± 34.89) μg/L and AFP (71.17±16.24) μg/L in liver cirrhotic group, and the differences of the two groups were statistically significant (t= 93.485, t =250.924; average P 0.05 ). Conclusion GP73 is highly expressed in the serum of PHC patients, which may be associated with the occurrence and development of liver cancer. Early detection of Serum GP73 should be helpful for early diagnosis of PHC.%目的 探讨血清高尔基体蛋白73(GP73)在原发性肝癌(primary hepatic carcinoma,PHC)患者血清中的表达及其临床意义.方法 采用酶联免疫吸附试验(ELISA)检测我院收治的47例PHC(肝癌组)及40例肝硬化(肝硬化组)血清中GP73,同时用电化学发光法检测血清甲胎蛋白(AFP),并将检测结果进行对比.结果 GP73和AFP测定值肝癌组分别为(220.44±89.71) μg/L、(404.06±135.43) μg/L,肝硬化组分别为(112.67 +34.89) μg/L、(71.17±16.24) μg/L,组间比较差异均有统计学意义(t=93.485,t=250.924；P均＜0.001).GP73和AFP阳性率肝癌组分别为85.11％ (40/47)、61.70％(29/47),肝硬化组分别为15.00％ (6/40)、22.50％(9/40),组间比较差异均有统计学意义(X2=70.654,X2=31.284;P均＜0.001).肝癌组GP73异常与合并肝硬化或淋巴结转移有关(t=2.061,=2.133；P均＜0.05),与肿瘤大小及临床分期无关(t=0.560,t=0.573;P均＞0.05).结论 肝癌患者血清高表达GP73,可能与肝癌的发生、发展有关,检测GP73有助于PHC早期诊断.
展开▼
